Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments

The prevalence of myopia and its complications has risen considerably in recent decades, particularly among children and teenagers. This trend is also spreading in Europe, driven by the increase in screen time and the intensive use of new technologies and social media, particularly among the younger generation.

Several treatment options are available today, including pharmacological treatments with atropine eye drops, as well as optical myopia control systems in the form of glasses or contact lenses.

These different treatments have been used in clinical practice at Saint-Étienne University Hospital since 2017 for atropine, and more recently with the development of optical myopia control systems and their combinations.

Little clinical data has been published to date on these different treatment combinations in the French population.

The investigators would therefore like to set up a database to publish their results and share their experience.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myopia Eye Diseases Refractive Errors

Age range

Up to 25 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Saint-Étienne

Saint-Etienne, 42100, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control glasses or contact lenses, and their various combinations
patient affiliated with a social security organization
agreement of both parents or the patient if adult

Exclusion criteria

non compliance with treatment

Treatment and study plan

Demographic data collection

Other

Demographic data collection: age, gender, level of education/study, time spent in near vision, sports practice, medical history

Ophthalmological history

Other

Ophthalmological history: age of myopia discovery, parental refraction, previous refractions, presence of a braking treatment

Ophthalmological data at each examination

Other

Ophthalmological data at each examination: visual acuity, subjective refraction, cycloplegia with SKIACOL, axial length.

Potential adverse events

Other

Potential adverse events: halos, photophobia, stinging, infections, etc.

Primary outcomes

Database of active treatments for myopia

Time frame: Month 5

Database established with data from children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control spectacles or contact lenses, and their various combinations.

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Aug 13, 2025
Registry last updated: Aug 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed